Robust Expansion Of Human Blood-derived γδ T Cells Using A Chemically-defined Medium

Abstract

Abstract Gamma delta (γδ) T cells have recently emerged as an attractive candidate for cancer immunotherapy treatments due to their inherent cytotoxicity against cancer cells. Moreover, γδ T cells provide a platform for allogeneic cell therapies as they can recognize antigens independent of MHC recognition and do not cause graft-versus-host disease (GVHD). However, the lack of robust and GMP-compatible serum-free ex vivo expansion system for γδ T cells hinders the development of scalable expansion processes for advancing γδ T cell immunotherapies. In the current study, we characterize the expansion of human peripheral blood-derived γδ T cells from various donors using TheraPEAK ®T-VIVO™ Medium, a novel chemically-defined cell expansion medium which is free of undefined and animal-origin components. Peripheral blood mononuclear cells (PBMCs) stimulated with zoledronic acid resulted in more than 1,000 fold expansion of γδ T cells in only 14 days with TheraPEAK ®T-VIVO™ Medium containing 100 IU/mL human recombinant IL-2, without the need for human serum supplementation. Similarly, PBMCs stimulated with agonist antibodies targeting Vδ1 or Vδ2 T cell receptors (TCR) induced robust expansion of Vδ1 or Vδ2 T cells, respectively, in TheraPEAK ®T-VIVO™ Medium. Collectively, these data support the use of TheraPEAK ®T-VIVO™ Medium to advance the development of γδ T cell manufacturing processes.